30.76
0.05 (0.16%)
| Penutupan Terdahulu | 30.71 |
| Buka | 30.68 |
| Jumlah Dagangan | 476,113 |
| Purata Dagangan (3B) | 618,972 |
| Modal Pasaran | 1,716,854,016 |
| Harga / Pendapatan (P/E TTM) | 23.30 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.16 |
| Harga / Jualan (P/S) | 2.67 |
| Harga / Buku (P/B) | 1.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | 11.16% |
| Margin Operasi (TTM) | 11.23% |
| EPS Cair (TTM) | 1.32 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,204.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.31% |
| Nisbah Semasa (MRQ) | 2.35 |
| Aliran Tunai Operasi (OCF TTM) | 171.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 155.22 M |
| Pulangan Atas Aset (ROA TTM) | 2.90% |
| Pulangan Atas Ekuiti (ROE TTM) | 7.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Supernus Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.20% |
| % Dimiliki oleh Institusi | 110.99% |
| Julat 52 Minggu | ||
| Median | 36.00 (17.04%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 26 Feb 2025 | 36.00 (17.04%) | Pegang | 31.91 |
| 19 Feb 2025 | 36.00 (17.04%) | Pegang | 33.52 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Apr 2025 | Pengumuman | Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 |
| 04 Mar 2025 | Pengumuman | Supernus to Participate in Two Upcoming Investor Conferences |
| 27 Feb 2025 | Pengumuman | Supernus to Participate in the TD Cowen 45th Annual Health Care Conference |
| 25 Feb 2025 | Pengumuman | Supernus Announces Fourth Quarter and Full Year 2024 Financial Results |
| 18 Feb 2025 | Pengumuman | Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression |
| 11 Feb 2025 | Pengumuman | Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results |
| 04 Feb 2025 | Pengumuman | Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |